Patents by Inventor Robert Doyle

Robert Doyle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250154548
    Abstract: Provided herein are methods of nucleic acid synthesis. In some embodiments, a method of nucleic acid synthesis comprises selectively activating and deactivating an engineered terminal deoxynucleotidyl transferase (TdT). In some embodiments, a method of nucleic acid synthesis comprises activating a pH sensitive enzyme to digest and remove a TdT.
    Type: Application
    Filed: November 8, 2024
    Publication date: May 15, 2025
    Inventors: Cassie M. Bryan, Melissa Sprachman, Robert Doyle, William C. Records
  • Publication number: 20250042937
    Abstract: Methods and compositions are provided for oxidizing peptides and forming disulfide bonds. In some aspects, a rapid, green, and facile oxidation of peptides (e.g., cysteine containing peptides) is performed (e.g., to promote the formation of 1-3 or more disulfide bonds). In some aspects, methods are conducted in aqueous solutions, in air, utilizing a biocompatible corrin ring-containing compound (e.g., dicyanocobinamide). In some aspects, reaction times are under 1 hour and a simple one step removal of the catalyst can be performed.
    Type: Application
    Filed: August 1, 2024
    Publication date: February 6, 2025
    Applicant: Syracuse University
    Inventors: Robert Doyle, Alyssa Spear
  • Patent number: 12090208
    Abstract: The invention involves the coupling of compounds that can be bound by Haptocorrin (R-binder; Transcobalamin I; HC) to a target drug to improve pharmacokinetics, avoid undesirable side effects, and/or modify CNS access and localization. The pharmaceutical effect may be improved by conjugating the drug to haptocorrin binding substrate. This allows the conjugate to become bound to unsaturated haptocorrin in the blood, thereby protecting the drug from metabolism or excretion to increase protein half-life while not interfering with the efficacy of the protein drug. The conjugation may additionally prevent the drug from reaching the central nervous system or modify where the drug localizes and produces undesirable side effects such as nausea or hypophagia. Such a route also would prevent, in all case save for actual vitamin B12, binding by serum transcobalamin II (TCII), and thus not cause B12 deficiency with long term use.
    Type: Grant
    Filed: December 22, 2021
    Date of Patent: September 17, 2024
    Assignee: SYRACUSE UNIVERSITY
    Inventor: Robert Doyle
  • Patent number: 11771772
    Abstract: The present invention provides compositions and methods for lowering blood glucose. More specifically, the present invention provides compositions comprising a complex comprising IF and B12 conjugated to a peptide comprising a GLP-1 agonist. Advantageously, the composition may be delivered subcutaneously.
    Type: Grant
    Filed: April 26, 2021
    Date of Patent: October 3, 2023
    Assignees: Syracuse University, Xeragenx LLC
    Inventors: Robert Doyle, Jonathan D. Bortz, David S. Hermelin
  • Patent number: 11679182
    Abstract: A method of making a hydroxyl-terminated thioketal diol is provided, the method comprising reacting a thioketal ester with a non-pyrophoric reducing agent to form a hydroxyl-terminated thioketal diol. The hydroxyl-terminated thioketal diol can be 2,2-(propane-2,2-diylbis(sulfanediyl)) diethanol. The non-pyrophoric reducing agent can be a sodium aluminum hydride, for example, sodium bis (2-methoxyethoxy)aluminum hydride. The thioketal ester can be dimethyl 2,2-(propane-2,2-diylbis(sulfanediyl)) diacetate. A biodegradable matrix prepared by reacting a hydroxyl-terminated thioketal diol with an isocyanate is provided. A method of making a biodegradable polyurethane composite is also provided.
    Type: Grant
    Filed: May 24, 2021
    Date of Patent: June 20, 2023
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: Roger E. Harrington, Jerbrena C. Jacobs, Robert Doyle
  • Publication number: 20220257805
    Abstract: The present disclosure provides pharmaceutical formulations and methods for delivering a therapeutic, diagnostic, or imaging agent to CD206. In an aspect, the present disclosure encompasses a pharmaceutical formulation for administration. The pharmaceutical formulation comprises a recombinantly produced intrinsic factor (IF), wherein the IF has a glycosylation pattern that enables binding to CD206.
    Type: Application
    Filed: May 20, 2020
    Publication date: August 18, 2022
    Inventors: Jonathan Bortz, Robert Doyle, Jayme Workinger
  • Publication number: 20220184218
    Abstract: The invention involves the coupling of compounds that can be bound by Haptocorrin (R-binder; Transcobalamin I; HC) to a target drug to improve pharmacokinetics, avoid undesirable side effects, and/or modify CNS access and localization. The pharmaceutical effect may be improved by conjugating the drug to haptocorrin binding substrate. This allows the conjugate to become bound to unsaturated haptocorrin in the blood, thereby protecting the drug from metabolism or excretion to increase protein half-life while not interfering with the efficacy of the protein drug. The conjugation may additionally prevent the drug from reaching the central nervous system or modify where the drug localizes and produces undesirable side effects such as nausea or hypophagia. Such a route also would prevent, in all case save for actual vitamin B12, binding by serum transcobalamin II (TCII), and thus not cause B12 deficiency with long term use.
    Type: Application
    Filed: December 22, 2021
    Publication date: June 16, 2022
    Applicant: SYRACUSE UNIVERSITY
    Inventor: Robert Doyle
  • Publication number: 20220127316
    Abstract: The present invention relates to engineered peptides and to methods of making engineered peptides. The present invention also relates to methods of treatment comprising administration of the engineered peptides to a subject in need thereof.
    Type: Application
    Filed: February 5, 2020
    Publication date: April 28, 2022
    Inventors: Matthew Robert Hayes, Bart C. De Jonghe, Tito Borner, Robert Doyle, Ian Tinsley
  • Publication number: 20220088203
    Abstract: The present invention provides compositions and methods for lowering blood glucose. More specifically, the present invention provides compositions comprising a complex comprising IF and B12 conjugated to a peptide comprising a GLP-1 agonist. Advantageously, the composition may be delivered subcutaneously.
    Type: Application
    Filed: April 26, 2021
    Publication date: March 24, 2022
    Applicant: Syracuse University
    Inventors: Robert Doyle, Jonathan D. Bortz, David S. Hermelin
  • Patent number: 11207415
    Abstract: The invention involves the coupling of compounds that can be bound by Haptocorrin (R-binder; Transcobalamin I; HC) to a target drug to improve pharmacokinetics, avoid undesirable side effects, and/or modify CNS access and localization. The pharmaceutical effect may be improved by conjugating the drug to haptocorrin binding substrate. This allows the conjugate to become bound to unsaturated haptocorrin in the blood, thereby protecting the drug from metabolism or excretion to increase protein half-life while not interfering with the efficacy of the protein drug. The conjugation may additionally prevent the drug from reaching the central nervous system or modify where the drug localizes and produces undesirable side effects such as nausea or hypophagia. Such a route also would prevent, in all case save for actual vitamin B12, binding by serum transcobalamin II (TCII), and thus not cause B12 deficiency with long term use.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: December 28, 2021
    Assignee: SYRACUSE UNIVERSITY
    Inventor: Robert Doyle
  • Publication number: 20210371374
    Abstract: The present disclosure relates to metal di-amino acid chelates and metal tri-amino acid chelates.
    Type: Application
    Filed: June 1, 2021
    Publication date: December 2, 2021
    Inventors: Robert Doyle, Ren Gonzalez
  • Publication number: 20210369768
    Abstract: The present disclosure relates to metal di-amino acid chelates and metal tri-amino acid chelates.
    Type: Application
    Filed: June 1, 2021
    Publication date: December 2, 2021
    Inventors: Robert Doyle, Ren Gonzalez
  • Patent number: 11163167
    Abstract: A head-mounted display device is provided, including an at least partially see-through display, an electrical device, and a flexible printed circuit board (FPC) arranged on a surface of a see-through portion of the display. The FPC may include a plurality of electrical traces electrically coupled to the electrical device. Each electrical trace may be separated from at least one other electrical trace by one or more respective see-through gaps. The FPC may further include a transparent material arranged between the electrical traces in each see-through gap.
    Type: Grant
    Filed: February 7, 2020
    Date of Patent: November 2, 2021
    Assignee: Microsoft Technology Licensing, LLC
    Inventors: Patrick Robert Doyle, Simon Hodgson
  • Publication number: 20210275726
    Abstract: A method of making a hydroxyl-terminated thioketal diol is provided, the method comprising reacting a thioketal ester with a non-pyrophoric reducing agent to form a hydroxyl-terminated thioketal diol. The hydroxyl-terminated thioketal diol can be 2,2-(propane-2,2-diylbis(sulfanediyl)) diethanol. The non-pyrophoric reducing agent can be a sodium aluminum hydride, for example, sodium bis (2-methoxyethoxy)aluminum hydride. The thioketal ester can be dimethyl 2,2-(propane-2,2-diylbis(sulfanediyl)) diacetate. A biodegradable matrix prepared by reacting a hydroxyl-terminated thioketal diol with an isocyanate is provided. A method of making a biodegradable polyurethane composite is also provided.
    Type: Application
    Filed: May 24, 2021
    Publication date: September 9, 2021
    Applicant: Warsaw Orthopedic, Inc.
    Inventors: Roger E. Harrington, Jerbrena C. Jacobs, Robert Doyle
  • Patent number: 11013831
    Abstract: A method of making a hydroxyl-terminated thioketal diol is provided, the method comprising reacting a thioketal ester with a non-pyrophoric reducing agent to form a hydroxyl-terminated thioketal diol. The hydroxyl-terminated thioketal diol can be 2,2-(propane-2,2-diylbis(sulfanediyl)) diethanol. The non-pyrophoric reducing agent can be a sodium aluminum hydride, for example, sodium bis(2-methoxyethoxy)aluminum hydride. The thioketal ester can be dimethyl 2,2-(propane-2,2-diylbis(sulfanediyl)) diacetate. A biodegradable matrix prepared by reacting a hydroxyl-terminated thioketal diol with an isocyanate is provided. A method of making a biodegradable polyurethane composite is also provided.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: May 25, 2021
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: Roger E. Harrington, Jerbrena C. Jacobs, Robert Doyle
  • Patent number: 10937531
    Abstract: A computer-assisted method to provide timely multi-channel notification of treatments to healthcare providers and patients, the method including receiving de-identified longitudinal medical records, treatment prescription records of healthcare providers, and notification data. Relationships between the healthcare providers, the anonymized patients, and the notifications are identified using the de-identified longitudinal medical records, the treatment prescription records of the healthcare providers, and the notification data. An impact of notifications being received by both the healthcare provider for the anonymized patient and the anonymized patient on whether the anonymized patient received the treatment is determined.
    Type: Grant
    Filed: April 9, 2018
    Date of Patent: March 2, 2021
    Assignee: IQVIA Inc.
    Inventors: Yunlong Wang, Emily Zhao, Yilian Yuan, Anthony Michael Wojeck, Robert Doyle, Yong Cai
  • Publication number: 20200261626
    Abstract: A method of making a hydroxyl-terminated thioketal diol is provided, the method comprising reacting a thioketal ester with a non-pyrophoric reducing agent to form a hydroxyl-terminated thioketal diol. The hydroxyl-terminated thioketal diol can be 2,2-(propane-2,2-diylbis(sulfanediyl)) diethanol. The non-pyrophoric reducing agent can be a sodium aluminum hydride, for example, sodium bis(2-methoxyethoxy)aluminum hydride. The thioketal ester can be dimethyl 2,2-(propane-2,2-diylbis(sulfanediyl)) diacetate. A biodegradable matrix prepared by reacting a hydroxyl-terminated thioketal diol with an isocyanate is provided. A method of making a biodegradable polyurethane composite is also provided.
    Type: Application
    Filed: February 20, 2019
    Publication date: August 20, 2020
    Inventors: Roger E. Harrington, Jerbrena C. Jacobs, Robert Doyle
  • Patent number: 10716827
    Abstract: The present invention relates to the digestion of peptides by pancreatic proteases and, more specifically, to compositions and methods for protecting against protease digestion.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: July 21, 2020
    Assignee: Syracuse University
    Inventors: Robert Doyle, Jonathan D. Bortz, David S. Hermelin
  • Publication number: 20190125883
    Abstract: The invention involves the coupling of compounds that can be bound by Haptocorrin (R-binder; Transcobalamin I; HC) to a target drug to improve pharmacokinetics, avoid undesirable side effects, and/or modify CNS access and localization. The pharmaceutical effect may be improved by conjugating the drug to haptocorrin binding substrate. This allows the conjugate to become bound to unsaturated haptocorrin in the blood, thereby protecting the drug from metabolism or excretion to increase protein half-life while not interfering with the efficacy of the protein drug. The conjugation may additionally prevent the drug from reaching the central nervous system or modify where the drug localizes and produces undesirable side effects such as nausea or hypophagia. Such a route also would prevent, in all case save for actual vitamin B12, binding by serum transcobalamin II (TCII), and thus not cause B12 deficiency with long term use.
    Type: Application
    Filed: April 14, 2017
    Publication date: May 2, 2019
    Applicant: SYRACUSE UNIVERSITY
    Inventor: Robert Doyle
  • Patent number: 10111932
    Abstract: Peptide sequences that can serve as agonists of both the glucagon-like peptide 1 receptor (GLP-IR) and the neuropeptide Y2 receptor (NPYR2). The peptide sequences include regions that correspond to certain aspect of natural substrates and known agonists of the glucagon-like peptide 1 receptor (GLP-IR) and the neuropeptide Y2 receptor (NPYR2) in a single sequence.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: October 30, 2018
    Assignee: Syracuse University
    Inventors: Robert Doyle, Ron Bonaccorso